EGFR and lung carcinoma: Additionally, while cSNX1.3 had minimal effect on the H1975 cell line, which has an EGFR driver mutation in the kinase domain (T790M), it was as ineffective as Sapitinib in the A549 lung cancer line with wildtype EGFR.